LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 14/Sep 23:19
Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma
Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function, today announced positive phase 2 end of study results
Articles similaires
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
drugs.com - 13/Sep 06:09
SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound...
First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
drugs.com - 05/Sep 04:09
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients
drugs.com - 16/Sep 14:09
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2024. Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final...
TC BioPharm to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008 to treat monkey pox
pharmabiz.com - 09/Sep 00:00
TC BioPharm (Holdings) PLC (TC BioPharm), a clinical stage biotechnology company developing platform allogeneic gamma─delta T cell therapies for...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Les derniers communiqués
-
Aucun élément